Use of analgesic drugs and risk of ovarian cancer-Results from a Danish case-control study.
Summary of "Use of analgesic drugs and risk of ovarian cancer-Results from a Danish case-control study."
Objective. The role of analgesic drug use in ovarian cancer development is not fully understood. We examined the association between analgesic use and risk of ovarian cancer. In addition, we examined whether the association differed according to histological types. Design. Population-based case-control study. Setting. Denmark in the period 1995-1999. Population. We included 756 women with epithelial ovarian cancer and 1564 randomly selected controls aged 35-79 years. Methods. Information on analgesic drug use was collected from personal interviews. Analgesic drugs were divided into the following categories: any analgesics, aspirin, non-aspirin non-steroidal anti-inflammatory drugs, paracetamol, and other analgesic drugs. The association between analgesic drug use and ovarian cancer risk was analyzed using multiple logistic regression models. Odds ratios (OR) and 95% confidence intervals (CI) were estimated. Main outcome measures. Epithelial ovarian cancer. Results. Women with a regular use of any analgesics (OR = 0.79; 95%
CI:
0.62 - 1.01) and aspirin (OR = 0.68; 95%
CI:
0.46 - 1.02) had a decreased risk of ovarian cancer, although not statistically significant. Regular use of non-aspirin non-steroidal anti-inflammatory drugs, paracetamol, and other analgesics did not decrease ovarian cancer risk. Use of any analgesics (OR = 0.72; 95%
CI:
0.53-0.98) and aspirin (OR = 0.60; 95%
CI:
0.36-1.00) resulted in a statistically significant decreased risk of serous ovarian cancer but not mucinous or other ovarian tumors. Conclusion. In accordance with most previous studies our results indicate a possible inverse association between analgesic use, particularly aspirin, and ovarian cancer risk.
Affiliation
Danish Cancer Society Research Center, Copenhagen, Department of Obstetrics and Gynecology, Skejby University Hospital, Aarhus, Department of Obstetrics and Gynecology, Copenhagen University Hospital, Copenhagen, Denmark.
Journal Details
This article was published in the following journal.
Name: Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22646488
- DOI: http://dx.doi.org/10.1111/j.1600-0412.2012.01472.x
Medical and Biotech [MESH] Definitions
Seer Program
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
Fenretinide
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Hamartoma Syndrome, Multiple
A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Pharmacoepidemiology
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
PubMed Articles
Background. A number of epidemiological studies have examined the association between use of dairy products and risk of ovarian cancer, but results are conflicting. Using data from a large Danish popu...
Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors.
PURPOSE: The aim of the study was to examine the potential association between a history of pelvic inflammatory disease (PID) and risk of epithelial ovarian cancer or ovarian borderline tumors. METHOD...
Høgdall EVS, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Høgdall CK. Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients. APMIS 2010; 118...
Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers.
Background Germline mutations in the BRCA1 and BRCA2 genes are associated with increased risks of breast and ovarian cancers. Although several common variants have been associated with breast cancer s...
OBJECTIVE: To examine Australian women's perceived risk of ovarian cancer, reasons for perceived risk levels, and knowledge of ovarian cancer symptoms at two timepoints (2003 and 2007). METHODS: A com...
Clinical Trials
Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
The purpose of this study is to determine whether the Risk of Ovarian Cancer Algorithm (ROMA) is effective in the determination of a woman's risk of cancer when she is scheduled to have su...
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer. PURPOSE: Screening trial to determine the significance of CA 12...
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is...
CA-125 in Screening Patients at High Risk for Ovarian Cancer
RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment....
CA 125 Algorithm for the Early Detection of Ovarian Cancer
The goal of this clinical research study is to evaluate a method involving a blood test, called CA-125, that may be helpful in the early detection of ovarian cancer in post-menopausal wome...
